Our findings underscore the importance of SMAD1 as a determinant of drug resistance in MM cells through across talk with NF-κB1, suggesting a SMAD1-based targeting strategy to overcome MM drug resistance. Here, SMAD1 is linked to Miyoshi myopathy.